Emyria’s Empax Clinics: Scalable Psychedelic Therapy Meets Growing National Demand
- Noel Ong
- 5 days ago
- 4 min read
Updated: 5 days ago
Announcement:
Emyria Limited (ASX: EMD) embodies the fusion of compassionate care, groundbreaking science, and a market in dire need of change. Recently, the company has gained attention by uniquely creating a scalable, evidence-based model for psychedelic-assisted therapy within licensed medical settings in Australia.
A Second Clinic—and a Strategic Footprint
On April 14, 2025, Emyria officially opened its second Empax Centre at Perth Clinic, a premier private psychiatric hospital. This move increases treatment capacity by 50% and is a pivotal step in the company’s national expansion plan.
Why is this significant? Because the Perth Clinic facility is licensed, it meets stringent criteria required by major health funders and insurers. In simple terms, this allows Emyria to deliver breakthrough care—such as MDMA and psilocybin-assisted therapy—to patients with treatment-resistant PTSD and depression, all under the watchful eye of a clinical governance structure that private payers demand.
Emyria’s Executive Chairman, Mr. Greg Hutchinson, commented:
“We are responding to growing patient demand and the expectations of major health funders,”
“Our expansion into licensed hospital settings demonstrates Emyria’s capacity to deliver scalable, evidence-based mental health care treatments.”
Why It Matters: The Mental Health Crisis Is Peaking
Mental illness affects 1 in 2 people globally, and in Australia, the cost of mental health is soaring, now rivalling expenditure on cancer. PTSD alone affects over 1.1 million Australians, while treatment-resistant depression (TR-D) impacts over 2.3 million.
The need for a new care model isn’t theoretical—it’s national.
Emyria’s leadership recognised that not only is the mental health system under pressure, but also that new treatments, particularly psychedelic-assisted therapies (P-AT), could offer durable and transformative relief. Australia is currently the only country in the world to reschedule MDMA and psilocybin for authorised psychiatric use—an opportunity Emyria is uniquely positioned to harness.
Durability and Data: The Proof is in the Outcomes
One of the most compelling aspects of Emyria’s offering is its growing pool of real-world evidence. Patients in its PTSD program have shown consistent improvement on both symptom severity (PCL-5 scores) and quality of life (ReQoL scores) three months after active treatment ends.
This isn’t just encouraging—it’s a paradigm shift. These results not only improve lives but help pave the way for policy change and payer support.
Dr. Michael Winlo, Emyria’s Founder and Chief Scientific Officer, explains:
“We’re building valuable real-world data assets in this emerging field—helping us improve our treatments, inform national care models, and support broader system adoption.”
Hard to Copy, Easy to Scale
Emyria’s delivery model is robust:
Licensed hospital environments
Specialist clinicians, including psychiatrists, psychologists, nurses, and occupational therapists
Secure, pharmaceutical-grade medication supply
Approved Authorised Prescribers by the TGA
This framework isn't easy to replicate, which makes Emyria a rare breed on the ASX—a first mover with intellectual property, clinical traction, and market-ready infrastructure.
Where Next?
Following this Perth expansion, Emyria is actively negotiating with East Coast hospital groups to open more Empax Centres. While no agreements are final yet, the company’s ambition is clear: a national network of payer-supported clinics that can deliver precision mental healthcare at scale.
With treatment costs averaging $20,000–$30,000 per patient and an estimated $36 billion addressable market, the potential is enormous.
Samso’s Concluding Comments
Emyria’s journey is not just about a new clinic—it’s about ushering in a new era of mental health care. They’re not following the trend—they’re building the infrastructure.
The ability to pair treatment-resistant depression and PTSD patients with therapies that are scientifically backed, clinically supervised, and payer-supported is game-changing. We’re seeing the early blueprint of a national care model that could finally start closing the gaps in our fractured mental health system.
With their focus on data, delivery, and durable results, Emyria has moved from being a bold idea to a real solution. It’s not often you see a small-cap ASX company building a moat this wide—and this meaningful.
For investors looking at impact and scalability, this is a story to watch especially with a market capitalisation of just over AUD $17M. Looking at the share price chart below, that is current to the close of trade on the 16th May 2025, this could be good timing do to some serious DYOR. The use of psychedelic-assisted therapy is something very interesting as I was just in a conversation on the weekend with a friend who is presently undergoing the same treatment.
Figure 1: The share price chart for Emyria Limited as of the close of trade on the 16th May 2025. (source: commsec).
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try and write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation see the benefit of what Samso is trying to achieve and have a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments